Abstract 1092P
Background
Previous studies demonstrate limited efficacy of immune checkpoint inhibitors in patients with irresectable acral melanoma (AM) compared to cutaneous melanoma (CM) in other locations. However, little is known about the outcomes of adjuvant therapy for resectable stage III-IV AM. This study aims to compare clinical outcomes after treatment with adjuvant anti-PD-1 in resectable stage III-IV AM and compare them to CM.
Methods
All patients with stage III-IV AM and CM who received adjuvant anti-PD-1 after complete resection between 2017 and 2022 were included from the prospective nationwide Dutch Melanoma Treatment Registry. We described baseline characteristics and analyzed the recurrence-free survival (RFS). A multivariable Cox regression analysis was performed to account for potential confounders age, performance status (ECOG), AJCC 8th edition disease stage, mutation status. Type of recurrence (locoregional or distant metastases) and toxicity rates will be presented at the conference.
Results
In total, 1977 patients (86 AM and 1891 CM) were included. At baseline, KIT mutations were more common in AM patients. In addition, AM patients more often had higher AJCC 8 disease stages. No other significantly different baseline characteristics were identified. Median follow-up was 16.4 months. The median RFS was 14.8 months (95%CI: 11.5-29.7) for the AM cohort and 37.4 months (95%CI: 32.1 - NR) for the CM cohort (p=.002)). After correcting for potential confounders, AM remained associated with higher risk of recurrence than CM (HRadj 1.55; 95%CI: 1.09-2.19; p=.014). Table: 1092P
Baseline characteristics and median RFS stratified by melanoma type.
AM (n=86) | CM (n=1891) | P-value | ||
Median age (IQR) | 65 [54, 72] | 64 [54, 73] | .984 | |
Gender (n (%) female) | 45 (52.3) | 793 (41.9) | .160 | |
AJCC8 stage (n (%)) | IIIA | 5 (5.7) | 130 (6.9) | .001 |
IIIB | 17 (19.5) | 599 (31.7) | ||
IIIC | 58 (66.7) | 713 (37.7) | ||
IIID | 2 (2.3) | 37 (2.0) | ||
IV | 2 (2.3) | 170 (9.0) | ||
Unknown | 3 (3.4) | 241 (12.8) | ||
Mutation (n (%)) | BRAF | 23 (26.7) | 804 (42.5) | .001 |
NRAS | 9 (10.5) | 441 (23.3) | ||
KIT | 7 (8.1) | 12 (0.6) | ||
Median RFS (months; 95% CI) | 14.8 (11.5-29.3) | 37.4 (32.1-NA) | .002 |
Conclusions
This study suggests that AM patients treated with adjuvant anti-PD-1 have shorter RFS than CM patients receiving the same treatment. Longer follow-up is needed to investigate overall survival and distant-metastasis-free survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J.B.A.G. Haanen: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Achilles Therapeutics, Ipsen, Merck Sharp & Dohme, Merck Serono, Pfizer, Molecular Partners, Novartis, Roche, Sanofi, Third Rock Venture, Iovance Biotherapeutics; Financial Interests, Institutional, Advisory Board, SAB member: BioNTech, Immunocore, Gadeta, Instil Bio, PokeAcel, T-Knife; Financial Interests, Personal, Advisory Board, SAB member: Neogene Therapeutics, Scenic; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, BioNTech US, Merck Sharp & Dohme, Amgen, Novartis, Asher Bio; Non-Financial Interests, Member: ASCO, AACR, SITC; Other, Other, Editorial Board ESMO Open: ESMO; Other, Other, Editor-in-Chief IOTECH: ESMO; Other, Editorial Board: Kidney Cancer. C.U. Blank: Financial Interests, Institutional, Advisory Board: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre; Financial Interests, Personal, Advisory Board: Third Rock Ventures; Financial Interests, Personal, Stocks/Shares: Immagene; Financial Interests, Personal, Stocks/Shares, intention to develop IFN signature algorithm: NewCo, no name yet; Financial Interests, Institutional, Coordinating PI: BMS, Novartis, NanoString, 4SC; Other, pending patent: WO 2021/177822 A1. M.J.B. Aarts: Financial Interests, Advisory Board: Amgen, BMS, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer; Financial Interests, Institutional, Research Grant: Merck-Pfizer. J.W. de Groot: Financial Interests, Advisory Role: BMS, Pierre Fabre, Servier, MSD, Novartis. G.A.P. Hospers: Financial Interests, Advisory Role: Amgen, BMS, Roche, MSD, Pfizer, Novartis, Pierre Fabre; Financial Interests, Institutional, Research Grant: BMS, Seerave. E. Kapiteijn: Financial Interests, Institutional, Advisory Board: BMS, Novartis, Pierre Fabre, Merck, Delcath, Bayer, Lilly; Financial Interests, Institutional, Coordinating PI: BMS, Pierre Fabre, Delcath. R.S. van Rijn: Financial Interests, Advisory Board: Pfizer; Financial Interests, Other, expert meeting fee: Roche. A.A.M. Van der Veldt: Financial Interests, Institutional, Advisory Role: BMS, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, Eisai, Merck; Financial Interests, Institutional, Advisory Board: MSD. M.J. Boers-Sonderen: Financial Interests, Advisory Role: Pierre Fabre, MSD, Novartis. F. Van Den Eertwegh: Financial Interests, Institutional, Research Grant, Grant for national trial: Roche; Financial Interests, Institutional, Research Grant, Grant for research project: BMS; Financial Interests, Institutional, Research Grant, Research grant for trial: Sanofi, Idera; Financial Interests, Institutional, Research Grant, Grant for trial: Teva; Non-Financial Interests, Advisory Role: BMS, Novartis, Pierre Fabre, MSD, Pfizer, Amgen, Ipsen, Merck. K.P.M. Suijkerbuijk: Financial Interests, Institutional, Advisory Board: Novartis, BMS, AbbVie, Pierre Fabre, MSD; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant: Novartis, TigaTx. All other authors have declared no conflicts of interest.
Resources from the same session
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12